Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Ferguson

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
American Journal of Clinical Oncology|December 7, 2019
Black Patients Experience Highest Rates of Cancer-associated Venous ThromboembolismNana Oduraa Addo-Tabiri, Rani Chudasama, Rhythm Vasudeva, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 21, 2024
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout TrialLindsay N Helget, Anne Davis-Karim, James R O'Dell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 16, 2023
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in GoutLindsay N Helget, James R O'Dell, Jeff A Newcomb, et al.
JAMIA Open|September 6, 2021
ProjectFlow: a configurable workflow management application for point of care researchRupali Dhond, Danne Elbers, Nilla Majahalme, et al.
Addiction Science & Clinical Practice|February 1, 2022
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veteransIsmene Petrakis, Sandra A Springer, Cynthia Davis, et al.
Seminars in Arthritis and Rheumatism|August 9, 2025
Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trialSamantha Kohn, Harlan Sayles, Lindsay N Helget, et al.
BMC Nephrology|July 27, 2016
The Rivas Cohort Study: design and baseline characteristics of a Nicaraguan cohortKailey Minnings, Madeline Fiore, Martha Mosco, et al.
Rheumatology (Oxford, England)|December 14, 2025
Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapyAustin M Wheeler, Tanner J Ourada, Spencer Q Jones, et al.
Arthritis Care & Research|August 7, 2025
Improvements in Health-Related Quality of Life with Treat-to-Target Urate-Lowering Therapy in Gout: A Post-hoc Analysis of a Randomized Multicenter TrialAustin Barry, Bryant R England, Harlan Sayles, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter TrialAustin Barry, Lindsay N Helget, Maria Androsenko, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
American Journal of Clinical Oncology|December 7, 2019
Black Patients Experience Highest Rates of Cancer-associated Venous ThromboembolismNana Oduraa Addo-Tabiri, Rani Chudasama, Rhythm Vasudeva, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 21, 2024
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout TrialLindsay N Helget, Anne Davis-Karim, James R O'Dell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 16, 2023
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in GoutLindsay N Helget, James R O'Dell, Jeff A Newcomb, et al.
JAMIA Open|September 6, 2021
ProjectFlow: a configurable workflow management application for point of care researchRupali Dhond, Danne Elbers, Nilla Majahalme, et al.
Addiction Science & Clinical Practice|February 1, 2022
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veteransIsmene Petrakis, Sandra A Springer, Cynthia Davis, et al.
Seminars in Arthritis and Rheumatism|August 9, 2025
Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trialSamantha Kohn, Harlan Sayles, Lindsay N Helget, et al.
BMC Nephrology|July 27, 2016
The Rivas Cohort Study: design and baseline characteristics of a Nicaraguan cohortKailey Minnings, Madeline Fiore, Martha Mosco, et al.
Rheumatology (Oxford, England)|December 14, 2025
Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapyAustin M Wheeler, Tanner J Ourada, Spencer Q Jones, et al.
Arthritis Care & Research|August 7, 2025
Improvements in Health-Related Quality of Life with Treat-to-Target Urate-Lowering Therapy in Gout: A Post-hoc Analysis of a Randomized Multicenter TrialAustin Barry, Bryant R England, Harlan Sayles, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter TrialAustin Barry, Lindsay N Helget, Maria Androsenko, et al.
Pageof 5